InforMax has adopted a stockholder rights plan designed to deter an unwanted takeover bid, the company said last week.

“The InforMax board of directors is taking this action to protect all stockholders of the company,” CEO Alex Titomirov said in a statement. “The rights are designed to provide the board with the flexibility and continued ability to determine the future of InforMax and to realize the value of our stockholders’ investment in the company.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.

Mar
13
Sponsored by
Agilent

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.